Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia. Accumulating experimental evidence shows the important linkage between tumor necrosis factor-α (TNF) and AD, but the exact role of TNF in AD is still not completely understood. Although TNF-inhibitors are successfully used for treating several diseases, total inhibition of TNF can cause side effects, particularly in neurological diseases. This is attributed to the opposing roles of the two TNF receptors. TNF receptor 1 (TNFR1) predominantly mediates inflammatory and pro-apoptotic signaling pathways, whereas TNF receptor 2 (TNFR2) is neuroprotective and promotes tissue regeneration. Therefore, the specific activation of TNFR2 signaling, either by directly targeting TNFR2 via TNFR2 agonists or by blocking TNFR1 signaling with TNFR1-selective antagonists, seems a promising strategy for AD therapy. This mini-review discusses the involvement of TNFR2 and its signaling pathway in AD and outlines its potential application as therapeutic target. A better understanding of the function of TNFR2 may lead to the development of a treatment for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793 · cited 1×
“TNF plays a vital role in the initiation and orchestration of inflammation and immunity (Aggarwal, 2003; Apostolaki et al., 2010; Fischer and Maier, 2015), and is potentially a key player in several neurodegenerative disorders, including Alzheimer’s disease (AD) (McAlpine and Tansey, 2008).”
BackgroundThe Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Koenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477 · cited 1×
“It has been suggested that resident microglia fail to efficiently phagocytose amyloid beta (Aβ) because of elevated levels of proinflammatory cytokines, including TNF (Koenigsknecht-Talboo and Landreth, 2005).”
BackgroundInflammatory markers and the risk of Alzheimer disease: The Framingham Study
Tan, Z. S., Beiser, A. S., Vasan, R. S., Roubenoff, R., Dinarello, C. A., Harris, T. B., Benjamin, E. J., Au, R., Kiel, D. P., Wolf, P. A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000263217.36439.da · Cited by 440
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390 · cited 1×
“Similarly, deletion of TNFR1 in an AD mouse model resulted in a reduction in the generation of Aβ plaques and an enhancement in learning and memory (He et al., 2007; Olleros et al., 2010), indicating the contribution of TNFR1 to neurodegeneration.”
BackgroundBlasko, I., Veerhuis, R., Stampfer-Kountchev, M., Saurwein-Teissl, M., Eikelenboom, P., & Grubeck-Loebenstein, B. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0321 · Cited by 258 · cited 1×
“Besides, cell culture studies showed that TNF increased apoptosis of neurons treated with Aβ (Blasko et al., 1997) and affected Aβ production (Blasko et al., 1999, 2000).”
Shi, J.-Q., Shen, W., Chen, J., Wang, B.-R., Zhong, L.-L., Zhu, Y.-W., Zhu, H.-Q., Zhang, Q.-Q., Zhang, Y.-D., & Xu, J. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.053 · Cited by 219 · cited 3×
“…TNFR2 as well as the existing potential therapeutic approaches targeting TNFR2, including solTNF inhibitor [e.g., xPro1595 (Olleros et al., 2010; Shi et al., 2011a)], TNFR1-specific antagonist [e.g., ATROSAB (Kim et al., 2016)], and TNFR2-specific agonists [e.g., TNF-scTNFR2 (Fischer et al.,…”
BackgroundInfluentialMadsen, P. M., Motti, D., Karmally, S., Szymkowski, D. E., Lambertsen, K. L., Bethea, J. R., & Brambilla, R. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.0211-16.2016 · Cited by 161
Patel, J. R., Williams, J. L., Muccigrosso, M. M., Liu, L., Sun, T., Rubin, J. B., & Klein, R. S. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1034-0 · Cited by 134 · cited 1×
“The neuroprotective role of TNFR2 signaling has been reported in several studies (Fontaine et al., 2002; Marchetti et al., 2004; Patel et al., 2012; Maier et al., 2013; Fischer et al., 2014).”
Cited by
Inflammation in Glaucoma: From the back to the front of the eye, and beyond
Baudouin, C., Kolko, M., Melik-Parsadaniantz, S., & Messmer, E. M. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100916 · Cited by 454
Dhapola, R., Hota, S. S., Sarma, P., Bhattacharyya, A., Medhi, B., & Reddy, D. H. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00889-6 · Cited by 383
“It reduces the levels of TNF in hippocampus region of brain and improves memory functions (Ortí-Casañ et al. 2019).”
BackgroundJurcău, M. C., Andronie-Cioara, F. L., Jurcău, A., Marcu, F., Ţiț, D. M., Pașcalău, N., & Nistor-Cseppentö, D. C. (2022) · Antioxidants · doi:10.3390/antiox11112167 · Cited by 226
“TNFR1 signaling can be also inhibited with TNFR1-specific antibodies, such as ATROSAB [146].”
BackgroundInfluentialAlkhalifa, A. E., Alkhalifa, O., Durdanovic, I., Ibrahim, D. R., & Maragkou, S. (2025) · Journal of Dementia and Alzheimer's Disease · doi:10.3390/jdad2020017 · Cited by 66
TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer’s Disease
Pillai, J. A., Bebek, G., Khrestian, M., Bena, J., Bergmann, C. C., Bush, W. S., Leverenz, J. B., & Bekris, L. M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.638922 · Cited by 29
“The rs976881 T/T reference genotype has been related to higher levels of sTNFR2 previously and activation of TNFR2 signaling has been posited as a promising strategy for AD therapy (Ortí-Casañ et al., 2019).”
Metadata
- Authors
- Ortí-Casañ, N., Wu, Y., Naudé, P. J. W., De Deyn, P. P., Zuhorn, I. S., & Eisel, U. L. M.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-02-04
- Volume
- 13
- Pages
- 49-49
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2911840604
- Cited by
- 77
- References
- 11
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer’s Disease. https://app.cochat.ai/papers/10.3389/fnins.2019.00049
- The paper
- Ortí-Casañ, N., Wu, Y., Naudé, P. J. W., De Deyn, P. P., Zuhorn, I. S., & Eisel, U. L. M. (2019). Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer’s Disease. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2019.00049
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.